{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T21:17:57Z","timestamp":1778879877095,"version":"3.51.4"},"reference-count":75,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinics in Liver Disease"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1016\/j.cld.2025.12.004","type":"journal-article","created":{"date-parts":[[2026,2,6]],"date-time":"2026-02-06T20:49:51Z","timestamp":1770410991000},"page":"323-342","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Noninvasive Testing for Metabolic Dysfunction-Associated Steatohepatitis (MASH) and Fibrosis"],"prefix":"10.1016","volume":"30","author":[{"given":"Markos","family":"Kalligeros","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laurent","family":"Castera","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emmanuel A.","family":"Tsochatzis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naim","family":"Alkhouri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.cld.2025.12.004_bib1","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1002\/hep.28431","article-title":"Global epidemiology of nonalcoholic fatty liver disease\u2014Meta-analytic assessment of prevalence, incidence, and outcomes","volume":"64","author":"Younossi","year":"2016","journal-title":"Hepatology"},{"issue":"Suppl","key":"10.1016\/j.cld.2025.12.004_bib2","doi-asserted-by":"crossref","first-page":"S32","DOI":"10.3350\/cmh.2024.0431","article-title":"Epidemiology of metabolic dysfunction-associated steatotic liver disease","volume":"31","author":"Younossi","year":"2025","journal-title":"Clin Mol Hepatol"},{"issue":"7","key":"10.1016\/j.cld.2025.12.004_bib3","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1056\/NEJMra2412865","article-title":"Metabolic dysfunction-associated steatotic liver disease","volume":"393","author":"Targher","year":"2025","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.cld.2025.12.004_bib4","doi-asserted-by":"crossref","first-page":"1913","DOI":"10.1002\/hep.30664","article-title":"The natural history of advanced fibrosis due to nonalcoholic steatohepatitis: data from the simtuzumab trials","volume":"70","author":"Sanyal","year":"2019","journal-title":"Hepatology"},{"issue":"11","key":"10.1016\/j.cld.2025.12.004_bib5","first-page":"672","article-title":"Noninvasive assessment to identify patients with At-Risk metabolic dysfunction-associated steatohepatitis","volume":"20","author":"Kalligeros","year":"2024","journal-title":"Gastroenterol Hepatol"},{"issue":"10","key":"10.1016\/j.cld.2025.12.004_bib6","doi-asserted-by":"crossref","first-page":"1741","DOI":"10.1136\/gutjnl-2025-335542","article-title":"Non-invasive tests of fibrosis in the management of MASLD: revolutionising diagnosis, progression and regression monitoring","volume":"74","author":"Feng","year":"2025","journal-title":"Gut"},{"issue":"10","key":"10.1016\/j.cld.2025.12.004_bib7","doi-asserted-by":"crossref","first-page":"2656","DOI":"10.1038\/s41591-023-02539-6","article-title":"Diagnostic performance of circulating biomarkers for non-alcoholic steatohepatitis","volume":"29","author":"Sanyal","year":"2023","journal-title":"Nat Med"},{"issue":"2","key":"10.1016\/j.cld.2025.12.004_bib8","doi-asserted-by":"crossref","first-page":"475","DOI":"10.3748\/wjg.v20.i2.475","article-title":"Limitations of liver biopsy and non-invasive diagnostic tests for the diagnosis of nonalcoholic fatty liver disease\/nonalcoholic steatohepatitis","volume":"20","author":"Sumida","year":"2014","journal-title":"World J Gastroenterol"},{"issue":"3","key":"10.1016\/j.cld.2025.12.004_bib9","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1055\/s-0044-1788277","article-title":"Noninvasive tests to assess fibrosis and disease severity in metabolic dysfunction-associated steatotic liver disease","volume":"44","author":"Tincopa","year":"2024","journal-title":"Semin Liver Dis"},{"issue":"5","key":"10.1016\/j.cld.2025.12.004_bib10","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.1097\/HEP.0000000000000323","article-title":"AASLD practice guidance on the clinical assessment and management of nonalcoholic fatty liver disease","volume":"77","author":"Rinella","year":"2023","journal-title":"Hepatology"},{"issue":"5","key":"10.1016\/j.cld.2025.12.004_bib11","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1053\/j.gastro.2025.02.044","article-title":"Global consensus recommendations for metabolic dysfunction-associated steatotic liver disease and steatohepatitis","volume":"169","author":"Younossi","year":"2025","journal-title":"Gastroenterology"},{"issue":"4","key":"10.1016\/j.cld.2025.12.004_bib12","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1053\/j.gastro.2023.06.013","article-title":"AGA clinical practice update on the role of noninvasive biomarkers in the evaluation and management of nonalcoholic fatty liver disease: expert review","volume":"165","author":"Wattacheril","year":"2023","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cld.2025.12.004_bib13","doi-asserted-by":"crossref","DOI":"10.1097\/HEP.0000000000001564","article-title":"Global performance of non-invasive tests in MASLD: insights from the G-MASLD study","author":"Younossi","year":"2025","journal-title":"Hepatology"},{"issue":"6","key":"10.1016\/j.cld.2025.12.004_bib14","doi-asserted-by":"crossref","first-page":"877","DOI":"10.2337\/dc24-2075","article-title":"Screening for metabolic dysfunction-associated steatotic liver disease-related advanced fibrosis in diabetology: a prospective multicenter study","volume":"48","author":"Caussy","year":"2025","journal-title":"Diabetes Care"},{"issue":"3","key":"10.1016\/j.cld.2025.12.004_bib15","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1111\/apt.17346","article-title":"A practical use of noninvasive tests in clinical practice to identify high-risk patients with nonalcoholic steatohepatitis","volume":"57","author":"Younossi","year":"2023","journal-title":"Aliment Pharmacol Ther"},{"issue":"4","key":"10.1016\/j.cld.2025.12.004_bib16","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1016\/S2468-1253(24)00437-0","article-title":"Staging liver fibrosis and cirrhosis using non-invasive tests in people with chronic hepatitis B to inform WHO 2024 guidelines: a systematic review and meta-analysis","volume":"10","author":"Liguori","year":"2025","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"17","key":"10.1016\/j.cld.2025.12.004_bib17","doi-asserted-by":"crossref","first-page":"1715","DOI":"10.1056\/NEJMra2403308","article-title":"Noninvasive assessment of liver fibrosis","volume":"393","author":"Castera","year":"2025","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.cld.2025.12.004_bib18","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1016\/j.jhep.2020.03.036","article-title":"Enhanced liver fibrosis test for the non-invasive diagnosis of fibrosis in patients with NAFLD: a systematic review and meta-analysis","volume":"73","author":"Vali","year":"2020","journal-title":"J Hepatol"},{"issue":"7","key":"10.1016\/j.cld.2025.12.004_bib19","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.2337\/dci24-0094","article-title":"Metabolic dysfunction-associated steatotic liver disease (MASLD) in people with diabetes: the need for screening and early intervention. A consensus report of the American diabetes association","volume":"48","author":"Cusi","year":"2025","journal-title":"Diabetes Care"},{"issue":"10","key":"10.1016\/j.cld.2025.12.004_bib20","doi-asserted-by":"crossref","first-page":"2312","DOI":"10.14309\/ajg.0000000000003268","article-title":"Optimal population screening strategies for liver fibrosis associated with metabolic dysfunction-associated steatotic liver disease","volume":"120","author":"Kim","year":"2025","journal-title":"Am J Gastroenterol"},{"issue":"1","key":"10.1016\/j.cld.2025.12.004_bib21","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1002\/hep.32545","article-title":"The steatosis-associated fibrosis estimator (SAFE) score: a tool to detect low-risk NAFLD in primary care","volume":"77","author":"Sripongpun","year":"2023","journal-title":"Hepatology"},{"issue":"1","key":"10.1016\/j.cld.2025.12.004_bib22","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1111\/liv.15718","article-title":"Diagnostic and prognostic performance of the SAFE score in non-alcoholic fatty liver disease","volume":"44","author":"Li","year":"2024","journal-title":"Liver Int"},{"issue":"1","key":"10.1016\/j.cld.2025.12.004_bib23","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/S2468-1253(24)00274-7","article-title":"Development, validation, and prognostic evaluation of LiverPRO for the prediction of significant liver fibrosis in primary care: a prospective cohort study","volume":"10","author":"Lindvig","year":"2025","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"6","key":"10.1016\/j.cld.2025.12.004_bib24","doi-asserted-by":"crossref","first-page":"1523","DOI":"10.1016\/j.cgh.2022.03.044","article-title":"Development and validation of a score for fibrotic nonalcoholic steatohepatitis","volume":"21","author":"Tavaglione","year":"2023","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.cld.2025.12.004_bib25","doi-asserted-by":"crossref","DOI":"10.1016\/j.diabres.2023.110679","article-title":"Noninvasive identification of probable fibrotic nonalcoholic steatohepatitis across the spectrum of glucose tolerance in the United States","volume":"199","author":"Ciardullo","year":"2023","journal-title":"Diabetes Res Clin Pract"},{"issue":"11","key":"10.1016\/j.cld.2025.12.004_bib26","doi-asserted-by":"crossref","first-page":"2577","DOI":"10.1111\/liv.15406","article-title":"Fibrosis nonalcoholic steatohepatitis index validation and applicability considering glycaemic severity and T2D duration","volume":"42","author":"Pina","year":"2022","journal-title":"Liver Int"},{"issue":"2","key":"10.1016\/j.cld.2025.12.004_bib27","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.jhep.2024.03.023","article-title":"Prospective head-to-head comparison of non-invasive scores for diagnosis of fibrotic MASH in patients with type 2 diabetes","volume":"81","author":"Castera","year":"2024","journal-title":"J Hepatol"},{"issue":"1","key":"10.1016\/j.cld.2025.12.004_bib28","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.cmet.2024.10.008","article-title":"A blood-based biomarker panel for non-invasive diagnosis of metabolic dysfunction-associated steatohepatitis","volume":"37","author":"Zhang","year":"2025","journal-title":"Cell Metab"},{"issue":"12","key":"10.1016\/j.cld.2025.12.004_bib29","doi-asserted-by":"crossref","DOI":"10.1097\/HC9.0000000000000586","article-title":"Serum protein risk stratification score for diagnostic evaluation of metabolic dysfunction-associated steatohepatitis","volume":"8","author":"Lai","year":"2024","journal-title":"Hepatol Commun"},{"key":"10.1016\/j.cld.2025.12.004_bib30","article-title":"Thrombospondin-2 is a performant biomarker of at-risk MASH and advanced MASH fibrosis in a large multicentre European cohort","author":"Ratziu","year":"2025","journal-title":"Gut"},{"issue":"3","key":"10.1016\/j.cld.2025.12.004_bib31","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1002\/hep.30163","article-title":"ADAPT: an algorithm incorporating PRO-C3 accurately identifies patients with NAFLD and advanced fibrosis","volume":"69","author":"Daniels","year":"2019","journal-title":"Hepatology"},{"issue":"7","key":"10.1016\/j.cld.2025.12.004_bib32","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1111\/jgh.16240","article-title":"Evaluation of blood-based PRO-C3 testing as a diagnostic marker for staging liver fibrosis: a systematic review and meta-analysis","volume":"38","author":"Liu","year":"2023","journal-title":"J Gastroenterol Hepatol"},{"issue":"8","key":"10.1016\/j.cld.2025.12.004_bib33","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1016\/S2468-1253(23)00017-1","article-title":"Biomarkers for staging fibrosis and non-alcoholic steatohepatitis in non-alcoholic fatty liver disease (the LITMUS project): a comparative diagnostic accuracy study","volume":"8","author":"Vali","year":"2023","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"6","key":"10.1016\/j.cld.2025.12.004_bib34","doi-asserted-by":"crossref","first-page":"1292","DOI":"10.1016\/j.jhep.2021.08.016","article-title":"Comparison of ADAPT, FIB-4 and APRI as non-invasive predictors of liver fibrosis and NASH within the CENTAUR screening population","volume":"75","author":"Nielsen","year":"2021","journal-title":"J Hepatol"},{"issue":"11","key":"10.1016\/j.cld.2025.12.004_bib35","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1016\/S2468-1253(20)30252-1","article-title":"A blood-based biomarker panel (NIS4) for non-invasive diagnosis of non-alcoholic steatohepatitis and liver fibrosis: a prospective derivation and global validation study","volume":"5","author":"Harrison","year":"2020","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"3","key":"10.1016\/j.cld.2025.12.004_bib36","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1016\/j.jhep.2023.04.031","article-title":"NIS2+\u2122, an optimisation of the blood-based biomarker NIS4\u00ae technology for the detection of at-risk NASH: a prospective derivation and validation study","volume":"79","author":"Harrison","year":"2023","journal-title":"J Hepatol"},{"issue":"1","key":"10.1016\/j.cld.2025.12.004_bib37","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1097\/HEP.0000000000000542","article-title":"Serum identification of at-risk MASH: the metabolomics-advanced steatohepatitis fibrosis score (MASEF)","volume":"79","author":"Noureddin","year":"2024","journal-title":"Hepatology"},{"issue":"7","key":"10.1016\/j.cld.2025.12.004_bib38","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1002\/ueg2.12589","article-title":"One-step non-invasive diagnosis of metabolic dysfunction-associated steatohepatitis and fibrosis in high-risk population","volume":"12","author":"Iruzubieta","year":"2024","journal-title":"United European Gastroenterol J"},{"issue":"4","key":"10.1016\/j.cld.2025.12.004_bib39","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1016\/j.jhep.2021.04.044","article-title":"Diagnostic accuracy of elastography and magnetic resonance imaging in patients with NAFLD: a systematic review and meta-analysis","volume":"75","author":"Selvaraj","year":"2021","journal-title":"J Hepatol"},{"issue":"5","key":"10.1016\/j.cld.2025.12.004_bib40","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1053\/j.gastro.2021.07.049","article-title":"Clinical care pathway for the risk stratification and management of patients with nonalcoholic fatty liver disease","volume":"161","author":"Kanwal","year":"2021","journal-title":"Gastroenterology"},{"issue":"5","key":"10.1016\/j.cld.2025.12.004_bib41","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1016\/j.jhep.2020.11.050","article-title":"Refining the baveno VI elastography criteria for the definition of compensated advanced chronic liver disease","volume":"74","author":"Papatheodoridi","year":"2021","journal-title":"J Hepatol"},{"issue":"2","key":"10.1016\/j.cld.2025.12.004_bib42","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1097\/HEP.0000000000001190","article-title":"Diagnostic accuracy of 2D-SWE ultrasound for liver fibrosis assessment in MASLD: a multilevel random effects model meta-analysis","volume":"82","author":"Indre","year":"2025","journal-title":"Hepatology"},{"issue":"9","key":"10.1016\/j.cld.2025.12.004_bib43","doi-asserted-by":"crossref","first-page":"5100","DOI":"10.1016\/j.acra.2025.04.009","article-title":"Prospective comparison of 2D-Shear wave elastography and vibration-controlled transient elastography in assessing liver fibrosis in metabolic dysfunction-associated steatotic liver disease","volume":"32","author":"Li","year":"2025","journal-title":"Acad Radiol"},{"issue":"1","key":"10.1016\/j.cld.2025.12.004_bib44","doi-asserted-by":"crossref","DOI":"10.1148\/radiol.242564","article-title":"Metabolic dysfunction-associated steatotic liver disease at quantitative US: international prospective study","volume":"316","author":"Huang","year":"2025","journal-title":"Radiology"},{"issue":"4","key":"10.1016\/j.cld.2025.12.004_bib45","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0249493","article-title":"Two-dimensional shear wave elastography and ultrasound-guided attenuation parameter for progressive non-alcoholic steatohepatitis","volume":"16","author":"Kuroda","year":"2021","journal-title":"PLoS One"},{"issue":"3","key":"10.1016\/j.cld.2025.12.004_bib46","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1016\/j.jhep.2023.04.025","article-title":"An individual patient data meta-analysis to determine cut-offs for and confounders of NAFLD-fibrosis staging with magnetic resonance elastography","volume":"79","author":"Liang","year":"2023","journal-title":"J Hepatol"},{"issue":"10","key":"10.1016\/j.cld.2025.12.004_bib47","doi-asserted-by":"crossref","first-page":"1715","DOI":"10.1016\/j.dld.2024.04.031","article-title":"Inflammation activity affects liver stiffness measurement by magnetic resonance elastography in MASLD","volume":"56","author":"Wei","year":"2024","journal-title":"Dig Liver Dis"},{"issue":"4","key":"10.1016\/j.cld.2025.12.004_bib48","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1097\/HEP.0000000000000417","article-title":"Head-to-head comparison of magnetic resonance elastography-based liver stiffness, fat fraction, and T1 relaxation time in identifying at-risk NASH","volume":"78","author":"Li","year":"2023","journal-title":"Hepatology"},{"issue":"6","key":"10.1016\/j.cld.2025.12.004_bib49","doi-asserted-by":"crossref","first-page":"3882","DOI":"10.1007\/s00330-023-10441-5","article-title":"A combination of non-invasive tests for the detection of significant fibrosis in patients with metabolic dysfunction-associated steatotic liver disease is not superior to magnetic resonance elastography alone","volume":"34","author":"Duman","year":"2024","journal-title":"Eur Radiol"},{"issue":"1","key":"10.1016\/j.cld.2025.12.004_bib50","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1186\/s12876-025-04017-4","article-title":"The diagnostic value of MRI-PDFF in hepatic steatosis of patients with metabolic dysfunction-associated steatotic liver disease: a systematic review and meta-analysis","volume":"25","author":"Zhang","year":"2025","journal-title":"BMC Gastroenterol"},{"issue":"4","key":"10.1016\/j.cld.2025.12.004_bib51","doi-asserted-by":"crossref","first-page":"1794","DOI":"10.1007\/s00330-024-11001-1","article-title":"Evaluation of MRI proton density fat fraction in hepatic steatosis: a systematic review and meta-analysis","volume":"35","author":"Azizi","year":"2025","journal-title":"Eur Radiol"},{"issue":"1","key":"10.1016\/j.cld.2025.12.004_bib52","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1097\/HEP.0000000000001318","article-title":"Proton density fat fraction for diagnosis of metabolic dysfunction-associated steatotic liver disease","volume":"83","author":"Panagiotopoulos","year":"2026","journal-title":"Hepatology"},{"issue":"5","key":"10.1016\/j.cld.2025.12.004_bib53","doi-asserted-by":"crossref","first-page":"1428","DOI":"10.1053\/j.gastro.2018.07.018","article-title":"Association between magnetic resonance imaging-proton density fat fraction and liver histology features in patients with nonalcoholic fatty liver disease or nonalcoholic steatohepatitis","volume":"155","author":"Wildman-Tobriner","year":"2018","journal-title":"Gastroenterology"},{"issue":"7","key":"10.1016\/j.cld.2025.12.004_bib54","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1016\/S2468-1253(23)00066-3","article-title":"Non-invasive diagnosis and monitoring of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis","volume":"8","author":"Tincopa","year":"2023","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"11","key":"10.1016\/j.cld.2025.12.004_bib55","doi-asserted-by":"crossref","first-page":"2451","DOI":"10.1016\/j.cgh.2021.09.041","article-title":"Clinical utility of magnetic resonance imaging biomarkers for identifying nonalcoholic steatohepatitis patients at high risk of progression: a multicenter pooled data and meta-analysis","volume":"20","author":"Andersson","year":"2022","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"7","key":"10.1016\/j.cld.2025.12.004_bib56","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1136\/gutjnl-2022-328689","article-title":"Diagnostic accuracy of FibroScan-AST (FAST) score for the non-invasive identification of patients with fibrotic non-alcoholic steatohepatitis: a systematic review and meta-analysis","volume":"72","author":"Ravaioli","year":"2023","journal-title":"Gut"},{"issue":"12","key":"10.1016\/j.cld.2025.12.004_bib57","doi-asserted-by":"crossref","first-page":"2582","DOI":"10.1111\/jgh.16770","article-title":"FibroScan-AST score for diagnosing fibrotic MASH: a systematic review and meta-analysis of diagnostic test accuracy studies","volume":"39","author":"Malandris","year":"2024","journal-title":"J Gastroenterol Hepatol"},{"issue":"4","key":"10.1016\/j.cld.2025.12.004_bib58","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1016\/j.jhep.2024.05.021","article-title":"Agile scores in MASLD and ALD: external validation and their utility in clinical algorithms","volume":"81","author":"Papatheodoridi","year":"2024","journal-title":"J Hepatol"},{"issue":"5","key":"10.1016\/j.cld.2025.12.004_bib59","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1097\/HEP.0000000000000694","article-title":"Diagnostic accuracy of AGILE 3+ score for advanced fibrosis in patients with NAFLD: a systematic review and meta-analysis","volume":"79","author":"Dalbeni","year":"2024","journal-title":"Hepatology"},{"issue":"4","key":"10.1016\/j.cld.2025.12.004_bib60","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1016\/j.jhep.2021.11.012","article-title":"MRI-based (MAST) score accurately identifies patients with NASH and significant fibrosis","volume":"76","author":"Noureddin","year":"2022","journal-title":"J Hepatol"},{"issue":"8","key":"10.1016\/j.cld.2025.12.004_bib61","doi-asserted-by":"crossref","first-page":"1656","DOI":"10.1111\/jgh.16589","article-title":"Performance of MAST, FAST, and MEFIB in predicting metabolic dysfunction-associated steatohepatitis","volume":"39","author":"Qi","year":"2024","journal-title":"J Gastroenterol Hepatol"},{"issue":"6","key":"10.1016\/j.cld.2025.12.004_bib62","doi-asserted-by":"crossref","first-page":"1482","DOI":"10.1016\/j.jhep.2022.07.020","article-title":"Head-to-head comparison between MEFIB, MAST, and FAST for detecting stage 2 fibrosis or higher among patients with NAFLD","volume":"77","author":"Kim","year":"2022","journal-title":"J Hepatol"},{"issue":"10","key":"10.1016\/j.cld.2025.12.004_bib63","doi-asserted-by":"crossref","first-page":"1946","DOI":"10.1136\/gutjnl-2020-322976","article-title":"MRE combined with FIB-4 (MEFIB) index in detection of candidates for pharmacological treatment of NASH-related fibrosis","volume":"70","author":"Jung","year":"2021","journal-title":"Gut"},{"issue":"5","key":"10.1016\/j.cld.2025.12.004_bib64","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1016\/j.cgh.2024.07.045","article-title":"acFibroMASH index for the diagnosis of fibrotic MASH and prediction of liver-related events: an international multicenter study","volume":"23","author":"Feng","year":"2025","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.cld.2025.12.004_bib65","article-title":"ALADDIN: a machine learning approach to enhance the prediction of significant fibrosis or higher in metabolic dysfunction-associated steatotic liver disease","author":"Alkhouri","year":"2025","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.cld.2025.12.004_bib66","doi-asserted-by":"crossref","DOI":"10.1097\/HEP.0000000000001617","article-title":"Predictors of fibrosis, clinical events and mortality in MASLD: data from the Global-MASLD study","author":"Younossi","year":"2025","journal-title":"Hepatology"},{"issue":"15","key":"10.1016\/j.cld.2025.12.004_bib67","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1001\/jama.2024.1447","article-title":"Vibration-controlled transient elastography scores to predict liver-related events in steatotic liver disease","volume":"331","author":"Lin","year":"2024","journal-title":"JAMA"},{"issue":"4","key":"10.1016\/j.cld.2025.12.004_bib68","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1016\/j.jhep.2024.05.008","article-title":"Increases and decreases in liver stiffness measurement are independently associated with the risk of liver-related events in NAFLD","volume":"81","author":"Gawrieh","year":"2024","journal-title":"J Hepatol"},{"issue":"10406","key":"10.1016\/j.cld.2025.12.004_bib69","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1016\/S0140-6736(23)01174-1","article-title":"Development, validation, and prognostic evaluation of a risk score for long-term liver-related outcomes in the general population: a multicohort study","volume":"402","author":"Serra-Burriel","year":"2023","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.cld.2025.12.004_bib70","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1097\/HEP.0000000000001112","article-title":"Resmetirom therapy for metabolic dysfunction-associated steatotic liver disease: october 2024 updates to AASLD practice guidance","volume":"81","author":"Chen","year":"2025","journal-title":"Hepatology"},{"key":"10.1016\/j.cld.2025.12.004_bib71","article-title":"Semaglutide therapy for metabolic dysfunction-associated steatohepatitis: november 2025 updates to AASLD practice guidance","author":"Bansal","year":"2025","journal-title":"Hepatology"},{"issue":"8","key":"10.1016\/j.cld.2025.12.004_bib72","doi-asserted-by":"crossref","first-page":"1990","DOI":"10.1111\/liv.15941","article-title":"Use of non-invasive diagnostic tools for metabolic dysfunction-associated steatohepatitis: a qualitative exploration of challenges and barriers","volume":"44","author":"Tsochatzis","year":"2024","journal-title":"Liver Int"},{"issue":"9-a Suppl","key":"10.1016\/j.cld.2025.12.004_bib73","first-page":"S1","article-title":"Nonalcoholic steatohepatitis\/metabolic dysfunction-associated steatohepatitis emerging market: preparing managed care for early intervention, equitable access, and integrating the patient perspective","volume":"30","author":"Flavin","year":"2024","journal-title":"J Manag Care Spec Pharm"},{"issue":"4","key":"10.1016\/j.cld.2025.12.004_bib74","doi-asserted-by":"crossref","first-page":"272","DOI":"10.7326\/M19-3171","article-title":"National Institutes of health pathways to prevention workshop: achieving health equity in preventive services","volume":"172","author":"Carey","year":"2020","journal-title":"Ann Intern Med"},{"issue":"11","key":"10.1016\/j.cld.2025.12.004_bib75","doi-asserted-by":"crossref","first-page":"1376","DOI":"10.1001\/jamainternmed.2025.4769","article-title":"Targeting MASLD and MASH in the US hispanic\/latino population: a review","volume":"185","author":"Cumpian","year":"2025","journal-title":"JAMA Intern Med"}],"container-title":["Clinics in Liver Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1089326125001060?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1089326125001060?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T20:59:21Z","timestamp":1778878761000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1089326125001060"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":75,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["S1089326125001060"],"URL":"https:\/\/doi.org\/10.1016\/j.cld.2025.12.004","relation":{},"ISSN":["1089-3261"],"issn-type":[{"value":"1089-3261","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Noninvasive Testing for Metabolic Dysfunction-Associated Steatohepatitis (MASH) and Fibrosis","name":"articletitle","label":"Article Title"},{"value":"Clinics in Liver Disease","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cld.2025.12.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}